{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"56"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"Brentuximab Vedotin"},{"description":"Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\\^2, tablets, orally, once daily with meals for up to 48 weeks.","id":"OG001","title":"Methotrexate or Bexarotene"}],"paramType":"NUMBER","populationDescription":"The Safety population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"First dose of study drug through 30 days after last dose of study drug (Up to 450 days)","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"participants"}